AMARIN CORP PLCUK (AMRN) Stock Profile — Insider Trades & Financials

Revenue$49.2M

Net Income-$1.2M

EPS$-0.09

Gross Margin47.1%

Market Cap$6.1B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Aaron Berg

CEO & Executive Director

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Founded: 1989
Employees: 80

⚡

Core Efficiency

ROE?

-0.27%

ROA?

-0.18%

D/E Ratio?

0.46

Op. Margin?

-12.85%

📊

Profitability Ratios

Net Margin?

-2.49%

Loading company sections...

AMARIN CORP PLCUK

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness